BioSpace News Archive

Glaukos Corporation (NYSE: GKOS), today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the iPRIME™ Viscodelivery System, a sterile, single-use, minimally-invasive device for the delivery of viscoelastic fluid during ophthalmic surgery.

Quidel Corporation, a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced that it expects total revenues in the fourth quarter of 2021 to be in the range of $633 million to $637 million and full year total revenues to be in the range of $1,695 million to $1,699 million.

Sensus Healthcare, Inc. will present at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022.

Micron Solutions, Inc. announced today the appointment of Mr. Martin Johnson as Executive Vice President of Sales and Strategy.

This innovative approach takes advantage of existing acquired immunity (generated, for example, through vaccination against pathogens) by including pathogen specific peptides into the company’s PeptiCRAd platform.

Milestone Scientific Inc today announced that Dr. Harsh Govil, MD, MPH, whose practice is based in Statesville, NC, has begun incorporating the CompuFlo ® Epidural instrument into his practice for pain management, following a successful evaluation.

Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock.

ResMed announced it plans to release financial and operational results for the second quarter of fiscal year 2022 on Thursday, January 27, 2022, after the New York Stock Exchange closes.

ContraFect Corporation, a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces that it has received an additional award from the Cystic Fibrosis Foundation.

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the addition of Elaine R. Mardis, Ph.D., to the Company’s Board of Directors.